The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Biotechnology
Lepu Biopharma Co., Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.52% HKD6.47
America/New_York / 3 mai 2024 @ 03:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10 385 mill |
| EPS: | -0.0100 |
| P/E: | -647.00 |
| Earnings Date: | Jun 14, 2024 |
| SharesOutstanding: | 1 605.18 mill |
| Avg Daily Volume: | 1.685 mill |
| RATING 2024-05-02 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -647.00 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -18.16x |
| Company: PE -647.00 | industry: PE 35.62 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD-0.645 (-109.96%) HKD-7.11 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 6.21 - 6.73 ( +/- 4.05%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD6.47 (4.52% ) |
| Volume | 0.434 mill |
| Avg. Vol. | 1.685 mill |
| % of Avg. Vol | 25.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 2157.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
2157.HK
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.